Recruitment
Participants will be recruited at a number of entry or exit points including outpatient clinics and their waitlists, emergency department (ED) discharges, and rapid assessment clinic discharges. Outpatient clinics include youth mental health services (age 16 and over only), adult general psychiatry consultation services (typically serving mood and anxiety disorders), psychotherapy services, post-traumatic stress and trauma therapy services, an outpatient substance use program, and a borderline personality disorder clinic. These recruitment settings were selected because: 1) they serve patients with the potential to benefit from the intervention, 2) they were identified by the participating sites and OTN as high priority settings, and 3) they have high volumes of use and turnover that will allow the implementation organization to reach their recruitment target. With the exception of the ED and rapid assessment clinics, the wait times to access these services vary from 4 months up to 2 years. Participation in the study will not affect wait list position or access to services.
Potential participants will be approached by a member of the clinical staff either by telephone, or in person in the clinic or ED. Hard-copy pamphlets or a website link to the study information will be provided. Once a potential participant indicates their interest, a research assistant (RA) or research co-ordinator (RC) will either meet them in person or contact via telephone to provide more information and obtain consent. Consent will include: 1) Consent to participate in the RCT (required), 2) Consent to be contacted for a qualitative interview (optional), 3) Consent to provide individual provincial health insurance plan (OHIP) number for linkage of survey data to health administrative data (optional), and 4) Consent for primary care provider to be notified of study enrollment (optional).
Separate consent to be re-randomized at 3 months will be obtained from ITG participants who opt-in to the nested intervention extension arm of the trial. This will be done with a question posed at the end of the 3 month data collection survey.
Data collection
All baseline and follow-up data will be entered into a REDCap™ database developed for the RCT. REDCap™ is confidential and is only accessible to the study personnel by secure login.
Outcome measures
Health administrative data will be retrieved after study completion from the Institute for Clinical Evaluative Sciences (ICES), a not-for-profit research institute encompassing a secure and accessible array of Ontario's health-related data. At ICES, individual-level health care and socio-demographic data from various sources are de-coded and linked using an encrypted health care number (ICES Key Number). We will extract individual data on inpatient, ED, outpatient health care utilization, as well as prescription drug costs (for people on social assistance or over age 65) during the study period and link to individual survey data using encrypted OHIP identifiers created by ICES authorized personnel. Individual health care costs will be determined using methods developed for use with Ontario data [
37].
We will track incremental costs associated with BWW using unit prices from expenditures related to its use (capital and operating costs such as license fees) as well as human resources required to support its implementation.
Adverse events
There is a growing consensus that adverse events (AEs) need to be evaluated in behavioural intervention trials [
38,
39], as there is a theoretical risk of deterioration, especially if online self-help tools are misunderstood or not properly applied [
38]. We will compare pre-defined AEs (see Table
2) between the ITG and DTG participants at 3 months, and the ITG-e and ITG-n participants at 6 months for clinically important differences that may be a result of BWW. Moreover, an independent data safety and monitoring board (DSMB) comprised of three content and methodology experts assembled for this trial will review available AE data at two interim time points: after the first 150 participants have completed 3 months, and again after 500 participants have completed 3 months, to determine if any investigation is required and if the trial is safe to continue. Health administrative data will not be available within this timeframe and will not be reviewed by the DSMB. DSMB terms of reference are available from the study investigators.
Mental health Hospitalization | CSRI; Health administrative data | Number of hospitalizations on a psychiatric unit |
Mental health ED visit | CSRI; Health administrative data | Number of ED visits for a mental health reason |
Crisis service use | CSRI | Number of times using crisis supports |
Increased suicidal ideation | PHQ-9 item 9 | Increase in PHQ-9 item 9 score |
Death | Health administrative data | All-cause mortality |
Worsening depression or anxiety | PHQ-9, GAD-7 | Increase in PHQ-9 or GAD-7 score over the prior 3 months |
Declining social and community integration | CIQ | Decrease in CIQ score over the prior 3 months |
Worsening disability | EQ-5D-5 L | Decrease in EQ-5D-5L scores over the prior 3 months |
Medication discontinuation | Author question added to CSRI | Self-reported discontinuation of psychotropic medication without provider knowledge |
Data analysis
In order to meet stakeholder deliverables, analyses will be completed at 2 time points: 1) analysis of 3 month data once all 3 month data have been collected, and 2) analysis of 6 month data at study end. Health care administrative data will only be analyzed after study end.
The primary outcome, RAS-r at 3 months, will be analyzed with an intent-to-treat analysis using an ANCOVA controlling for baseline RAS-r score as well as treatment group, unadjusted and adjusted for baseline PHQ-9, baseline GAD-7, age, sex, education, relationship status, household income, duration of episode, and recruitment setting. In sensitivity analysis, we will repeat this using a marginal structural model to account for attrition.
The same analysis will be repeated for all secondary outcomes at 3 months controlling for baseline score and treatment group. Analysis of 3 month data will be completed after all 3 month data have been collected.
In the subset of ITG participants who opt in to the nested extension study, we will examine outcomes at 6 months between treatment groups. Analysis of primary and secondary outcomes will be repeated as described above, controlling for scores at both baseline and 3 months.
Second, we will examine engagement with the BWW among ITG participants. The number of logins and total time on the site will be separately predicted with age, gender, education, relationship status, living situation, household income, baseline belief in treatment credibility and outcome expectancy, baseline PHQ-9 and GAD-7 scores, duration of current episode, recruitment setting and outpatient mental health visits.